Skip to Content

GAVISCON COOL LIQUID

Active substance(s): CALCIUM CARBONATE / SODIUM ALGINATE / SODIUM BICARBONATE

PDF options:  View Fullscreen   Download PDF

PDF Transcript

SUMMARY OF PRODUCT CHARACTERISTICS

1

NAME OF THE MEDICINAL PRODUCT
Gaviscon Cool Liquid

2

QUALITATIVE AND QUANTITATIVE COMPOSITION
Gaviscon Cool Liquid contains 250mg sodium alginate BP, 133.5 mg sodium
bicarbonate Ph. Eur. and 80 mg calcium carbonate Ph. Eur. per 5 ml.

3

PHARMACEUTICAL FORM
Oral suspension.

4

CLINICAL PARTICULARS

4.1

Therapeutic indications
Gastric reflux, hearburn, flatulence associated with gastric reflux, heartburn of
pregnancy, all cases of epigastric and retrosternal distress where the
underlying cause is gastric reflux.

4.2

Posology and method of administration
For oral administration.
Adults and children over 12: 10-20 ml after meals and at bedtime.
Elderly: No dose modification is required in this age group.
Children 6-12 years: 5-10 ml after meals and at bedtime.
Children under 6 years: Not recommended.
If symptoms persist consult your doctor.

4.3

Contraindications
This medicinal product is contraindicated in patients with known or suspected
hypersensitivity to the active substances or to any of the excipients listed in

section 6.1, including methyl parahydroxybenzoate (E218) and propyl
parahydroxybenzoate (E216) (see section 4.4).

4.4

Special warnings and precautions for use
If symptoms do not improve after seven days, the clinical situation should be
reviewed.
Each 10 ml dose has a sodium content of 141 mg (6.2 mmol). This should be
taken into account when a highly restricted salt diet is recommended. e.g. in
some cases of congestive cardiac failure and renal impairment.
Each 10 ml dose contains 160 mg (1.6 mmol) of calcium carbonate. Care
needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis
and recurrent calcium containing renal calculi.
Contains
methyl
parahydroxybenzoate
(E218)
and
propyl
parahydroxybenzoate (E216) which may cause allergic reactions (possibly
delayed).

4.5

Interaction with other medicinal products and other forms of interaction
A time-interval of 2 hours should be considered between Gaviscon intake and
the administration of other medicinal products, especially tetracyclines,
digoxine, fluoroquinolone, iron salt, ketoconazole, neuroleptics, thyroid
hormones, penicillamine, beta-blockers (atenolol, metoprolol, propanolol),
glucocorticoid, chloroquine and biphosphonates (diphosphonates) and
estramustine. See also 4.4.

4.6

Fertility, Pregnancy and lactation
Pregnancy:
Clinical studies in more than 500 pregnant women as well as a large amount of
data from post-marketing experience indicate no malformative nor feto/
neonatal toxicity of the active substances.
Gaviscon can be used during pregnancy, if clinically needed.
Breast feeding:
No effects of the active substances have been shown in breastfed
newborns/infants of treated mothers. Gaviscon can be used during breastfeeding.
Fertility:
Pre-clinical investigations have revealed alginate has no negative effect on
parental or offspring fertility or reproduction.
Clinical data do not suggest that Gaviscon has an effect on human fertility.

4.7

Effects on ability to drive and use machines
None.

4.8

Undesirable effects
Adverse reactions have been ranked under headings of frequency using the
following convention: very common (1/10), common (1/100 and <1/10),
uncommon (1/1000 and <1/100), rare (1/10,000 and <1/1000), very rare (<
1/10,000) and not known (cannot be estimated from the available data).
System Organ Class
Immune System
Disorders
Respiratory, Thoracic and
Mediastinal Disorders

Frequency
Very rare

Very rare

Adverse Event
Anaphylactic and anaphylactoid reactions.
Hypersensitivity reactions such as
urticaria.
Respiratory effects such as bronchospasm.

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal
product is important. It allows continued monitoring of the benefit/risk balance
of the medicinal product. Healthcare professionals are asked to report any
suspected adverse reactions via the Yellow Card Scheme at:
www.mhra.gov.uk/yellowcard

4.9

Overdose
In the event of overdosage symptomatic treatment should be given. The
patient may notice abdominal distension.

5

PHARMACOLOGICAL PROPERTIES

5.1

Pharmacodynamic properties
On ingestion the product reacts rapidly with gastric acid to form a raft of
alginic acid gel having a near neutral pH and which floats on the stomach
contents, quickly and effectively impeding gastro-oesophageal reflux, for up
to 4 hours. In severe cases the raft itself may be refluxed into the oesophagus,
in preference to the stomach contents, and exert a demulcent effect.

5.2

Pharmacokinetic properties
The mode of action of Gaviscon Cool Liquid is physical and does not depend
on absorption into the systemic circulation.

5.3

Preclinical safety data
No preclinical findings of relevance to the prescriber have been reported

6

PHARMACEUTICAL PARTICULARS

6.1

List of excipients
Carbomer
E218 (Methyl parahydroxybenzoate)
E216 (Propyl parahydroxybenzoate)
Saccharin sodium
Mint flavour no. 4
Mint flavour no. 5
Sodium hydroxide
Purified water

6.2

Incompatibilities
None known.

6.3

Shelf life
Two years.

6.4

Special precautions for storage
Do not store above 30°C. Do not refrigerate or freeze.

6.5

Nature and contents of container
Amber glass bottles with a polypropylene cap with a polyethylene tamperevident band lined with expanded polyethylene wad and containing 100, 150,
200, 300, 500 or 600 ml.

6.6

Special precautions for disposal
To be taken orally. If desired the standard dose of Gaviscon Cool Liquid may
be taken diluted with not more than an equal quantity of water well stirred.

7

MARKETING AUTHORISATION HOLDER
Reckitt Benckiser Healthcare (UK) Limited,
103 – 105 Bath Road,
Slough,
SL1 3UH,
United Kingdom

8

MARKETING AUTHORISATION NUMBER(S)
PL 00063/0739

9

DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
06/02/2006

10

DATE OF REVISION OF THE TEXT
16/11/2017

+ Expand Transcript

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide